Share on StockTwits

Keryx Biopharmaceuticals (NASDAQ:KERX)‘s stock had its “buy” rating reaffirmed by equities research analysts at Maxim Group in a research note issued to investors on Tuesday.

Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 17.23 on Tuesday. Keryx Biopharmaceuticals has a 52 week low of $8.48 and a 52 week high of $17.52. The stock’s 50-day moving average is $15.4 and its 200-day moving average is $14.92. The company’s market cap is $1.582 billion. Keryx Biopharmaceuticals also was the target of unusually large options trading on Monday. Stock traders purchased 4,730 call options on the company. This is an increase of 289% compared to the typical volume of 1,215 call options.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company posted ($0.14) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.89 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on KERX. Analysts at FBR Capital Markets initiated coverage on shares of Keryx Biopharmaceuticals in a research note on Wednesday, August 13th. They set a “market perform” rating and a $16.00 price target on the stock. Analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $32.00 to $30.00 in a research note on Friday, August 8th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $22.89.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.